Norge -
norsk -
Statens legemiddelverk
apodorm 5 mg
actavis group ptc ehf - nitrazepam - tablett - 5 mg
Norge -
norsk -
Statens legemiddelverk
melphalan macure 50 mg
macure pharma aps - melfalanhydroklorid - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 50 mg
Norge -
norsk -
Statens legemiddelverk
alkeran 2 mg
aspen pharma trading limited - melfalan - tablett, filmdrasjert - 2 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immune sera og immunglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
Norge -
norsk -
Statens legemiddelverk
marcain spinal tung 5 mg/ ml
aspen pharma trading limited - bupivakainhydroklorid - injeksjonsvæske, oppløsning - 5 mg/ ml
Norge -
norsk -
Statens legemiddelverk
tribovax vet
intervet international bv - 5831 an - clostridium perfringens, type a, alfa toksoid / clostridium perfringens, type b/ c, beta toksoid / clostridium perfringens, type d, epsilon toksoid / clostridium chauvoei, inaktivert / clostridium novyi, inaktivert / clostridium septikum, inaktivert / clostridium tetani, inaktivert / clostridium sordellii, toksoid / clostridium haemolyticum, inaktivert - injeksjonsvæske, suspensjon